US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voya Infrastructure Industrials and Materials Fund

10.52

+0.03900.37%

Post-market: 10.520.00000.00%16:05 EDT

Volume:65.57K

Turnover:686.67K

Market Cap:202.80M

PE:- -

High:10.52

Open:10.48

Low:10.38

Close:10.48

Loading ...

Overview Company News Filings

ASE Demonstrates CPO that Improves Energy Efficiency for AI applications

ABT Stock Gains Following the Positive TRILUMINATE Trial Results

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System

Datavault AI Licenses Patented ADIO Technology to NYIAX, Ushering in a New Era of Ultrasonic Advertising

Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US

Simply Wall St.

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

Realtek to Showcase Datavault AI’s Acoustic Divisions WiSA E at Convergence India Expo, Featuring Solutions Supporting India’s AI and Blockchain Initiatives

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

Press Release: Voya Equity Closed End Funds Declare Distributions

NYIAX Technology Platform Powered by Nasdaq Collaborates with Datavault AI’s Patented Information Data Exchange® through Co-Marketing and Technology Alliance

First Patient Enrolled in Merit Medical’s PREEMIE Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IDE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","market":"US","secType":"STK","nameCN":"Voya Infrastructure Industrials and Materials Fund","latestPrice":10.519,"timestamp":1743537600000,"preClose":10.48,"halted":0,"volume":65568,"hourTrading":{"tag":"盘后","latestPrice":10.519,"preClose":10.519,"latestTime":"16:05 EDT","volume":56,"amount":588.057,"timestamp":1743537914798},"delay":0,"floatShares":0,"shares":19279000,"eps":0,"marketStatus":"Closed","change":0.039,"latestTime":"04-01 16:00:00 EDT","open":10.48,"high":10.52,"low":10.3801,"amount":686668.5313,"amplitude":0.013349,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743580800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":10.48,"aum":0,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":10.519,"preClose":10.519,"latestTime":"16:05 EDT","volume":56,"amount":588.057,"timestamp":1743537914798},"volumeRatio":1.306552},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.306552,"shares":19279000,"dividePrice":1.2,"high":10.52,"amplitude":0.013349,"preClose":10.48,"low":10.3801,"week52Low":9.8416,"pbRate":"--","week52High":11.766,"institutionHeld":0,"latestPrice":10.519,"eps":0,"divideRate":0.114079,"volume":65568,"delay":0,"ttmEps":0,"open":10.48,"prevYearClose":10.15,"prevWeekClose":10.55,"prevMonthClose":10.58,"prevQuarterClose":10.58,"fiveDayClose":10.63,"twentyDayClose":10.36,"sixtyDayClose":10.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDE\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524116931","title":"ASE Demonstrates CPO that Improves Energy Efficiency for AI applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2524116931","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524116931?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., April 01, 2025----Advanced Semiconductor Engineering, Inc. , a member of ASE Technology Holding Co., Ltd. , today announced that it has demonstrated a co-packaged optics  device that mounts multiple optical engines  directly onto a substrate, enabling <5pJ/bit power consumption and significant bandwidth increases. With today’s processing power requirements being extremely amplified by AI pervasion, there is unprecedented demand for bandwidth that must be addressed. ASE’s new configuration enables crucial on-package energy efficiency and bandwidth expansion while addressing further data center challenges by delivering improvement related to latency, data throughput, and scalability.ASE’s CPO solves the assembly challenge of multiple optical engines with an ASIC in an integrated package with a large body configuration of >75mm X 75mm. The benefits for both the networking and data center markets are significant. For networking, it provides a potential option to improve ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ase-demonstrates-cpo-improves-energy-130000457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4543","IDE","BK4141","BK4526","ASX"],"gpt_icon":0},{"id":"2524111166","title":"ABT Stock Gains Following the Positive TRILUMINATE Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524111166","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524111166?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:22","pubTimestamp":1743506520,"startTime":"0","endTime":"0","summary":"Abbott Laboratories ABT recently unveiled favorable TRILUMINATE Pivotal trial data at the American College of Cardiology's Annual Scientific Session , held in Chicago. The data demonstrated Abbott’s TriClip transcatheter edge-to-edge repair  system’s ability to treat tricuspid regurgitation . The system showed substantial and sustained improvements in the severity of TR after two years.The TriClip system is also found to reduce the rate of hospitalizations due to heart failure compared to medical therapy while offering long-term quality-of-life benefits for patients. The latest development is expected to bolster the company’s Structural Heart business.Following yesterday's announcement, Abbott shares rose 1.4%, closing at $132.65.The company currently offers a comprehensive portfolio of structural heart solutions for a range of conditions, enabling patients to achieve better health and an improved quality of life. Moreover, Abbott is an established leader in TEER space with its MitraCl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abt-stock-gains-following-positive-112200931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0267386448.USD","LU2506952170.USD","BK4212","LU1267930490.SGD","LU0154236417.USD","TR","BK4568","LU1914381329.SGD","LU1989763427.SGD","LU2506952097.USD","LU0353189763.USD","IE00B2B36J28.USD","BK4592","ABT","BK4581","LU2242649171.HKD","LU0006061336.USD","SG9999004303.SGD","LU1989764664.SGD","LU0211327993.USD","LU1023059063.AUD","BK4082","LU0048584097.USD","LU2244417387.USD","LU0345769631.USD","CAH","LU0240878834.USD","LU2506951958.HKD","LU2764262908.HKD","LU0072461881.USD","LU2764263039.SGD","IDE","LU0868494617.USD","LU0353189680.USD","LU0823417653.USD","LU1291159041.SGD","LU0345769128.USD","BK4504","LU1791710400.SGD","LU0823416689.USD","LU0882574055.USD","IE00BFTCPJ56.SGD","LU2362540622.SGD","MASI","LU0052756011.USD","BSX","LU1989763690.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2524019416","title":"Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524019416","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524019416?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053157/0/en/Fractyl-Health-Reports-Positive-Early-Data-Showing-Revita-Has-Potential-to-Prevent-Weight-Regain-After-GLP-1-Discontinuation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","IDE","BK4590","GLP","GUTS","BK4082"],"gpt_icon":0},{"id":"2524970260","title":"Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970260","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970260?lang=en_us&edition=fundamental","pubTime":"2025-04-01 05:00","pubTimestamp":1743454800,"startTime":"0","endTime":"0","summary":"Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052830/0/en/Glucotrack-Reports-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IDE","GCTK"],"gpt_icon":0},{"id":"2522306934","title":"Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306934","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306934?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:00","pubTimestamp":1743080400,"startTime":"0","endTime":"0","summary":"Abbott's Volt PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation. Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heart. Abbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer indication of contact between the Volt PFA catheter and targeted tissue. ABBOTT PARK, Ill., March 27, 2025 /PRNewswire/ -- Abbott  today announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation . With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies. The company will further expand use of Volt in EU markets throughout the second half of the year.Volt PFA Syste","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbott-receives-ce-mark-volt-130000876.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbott-receives-ce-mark-volt-130000876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4109","BK4082","BK4566","LU2133065610.SGD","SG9999002224.SGD","LU2468319806.SGD","BK4588","BK4581","LU2089984988.USD","LU0234572021.USD","LU1023059063.AUD","BK4504","EP","SG9999004303.SGD","IE00BFTCPJ56.SGD","LU1721429402.USD","IE00BJJMRZ35.SGD","IDE","LU2112291526.USD","BK4213","SGXZ23171101.USD","IE00BJT1NW94.SGD","LU0170899867.USD","IE00B2B36J28.USD","LU1691799644.USD","CE","ABT","LU0122379950.USD","BK4585","LU1989763427.SGD","PVI","SG9999002232.USD","LU2237957902.USD","IE0002141913.USD","LU1721429741.USD","BK4568","BK4533","LU1057294990.SGD","LU1914381329.SGD","BK4592","LU0868494617.USD","LU1061106388.HKD","LU2237957811.SGD","IE0009355771.USD","LU0266013472.USD","LU1989763690.USD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2522074303","title":"Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522074303","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522074303?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:25","pubTimestamp":1742909100,"startTime":"0","endTime":"0","summary":"At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target les","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048850/8028/en/Merit-Medical-Releases-12-Month-Efficacy-Results-of-the-WRAPSODY-Cell-Impermeable-Endoprosthesis-CIE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WAVE","LU1559883803.SGD","BK4585","BK4588","CE","MMSI","BK4109","IDE","LU0566484027.USD","BK4198","BK4539","BK4133"],"gpt_icon":0},{"id":"2522009664","title":"ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009664","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009664?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:16","pubTimestamp":1742908560,"startTime":"0","endTime":"0","summary":"Abbott ABT has received the FDA’s investigational device exemption  for its Coronary Intravascular Lithotripsy  system to evaluate the treatment of severe calcification in coronary arteries prior to stenting. The TECTONIC Coronary Artery Disease  Intravascular Lithotripsy  clinical trial will enroll up to 335 people in 47 sites in the United States.The company’s investigational Coronary IVL technology builds upon its existing vascular portfolio, part of the Medical Devices segment, and is designed to address the challenges of currently available IVL systems.Per a Research report, the global CAD market was valued at $22.07 billion in 2024 and is set to witness a compound annual rate of 8.9% through 2031. The rising CAD prevalence around the world fuels the market’s growth, along with higher funding for research and development of therapies and an increase in comorbid conditions, including atherosclerosis and hypertension.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abt-stock-gain-fda-ide-131600566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823417737.USD","ABT","LU2468319806.SGD","BK4568","SG9999002232.USD","LU0187121727.USD","BK4196","LU1983299246.USD","BSX","LU2362541513.USD","LU0211327993.USD","LU0251132253.USD","LU0310799852.SGD","LU2491050154.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","LU0011850046.USD","LU0162691827.USD","LU1267930490.SGD","IE0002141913.USD","CAH","LU1718418525.SGD","LU2506951958.HKD","LU1571399168.USD","LU2087625088.SGD","LU0072461881.USD","LU0114720955.EUR","LU0868494617.USD","BK4588","LU0154236417.USD","SG9999001440.SGD","LU0048584097.USD","LU2242649171.HKD","LU0170899867.USD","LU1791710400.SGD","LU0238689110.USD","LU0310800965.SGD","BK4533","LU1791710582.SGD","LU1989764748.USD","IDE","LU1291159041.SGD","BK4175","LU2506952097.USD","LU0122379950.USD","LU1914381329.SGD","IE0009355771.USD","LU2237957902.USD"],"gpt_icon":1},{"id":"2522002742","title":"Datavault AI Licenses Patented ADIO Technology to NYIAX, Ushering in a New Era of Ultrasonic Advertising","url":"https://stock-news.laohu8.com/highlight/detail?id=2522002742","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522002742?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:57","pubTimestamp":1742903820,"startTime":"0","endTime":"0","summary":"Licensing Deal Strengthens Focus on Information Data Exchange While Introducing a Privacy-First Advertising Category. BEAVERTON, Ore., March 25, 2025----Datavault AI Inc. , a leader in AI-driven data valuation and monetization, today announced a strategic licensing agreement with NYIAX, the Nasdaq-powered trading platform. This agreement integrates Datavault AI’s patented ADIO technology into NYIAX’s cutting-edge advertising exchange, creating one of the world’s first fully functional ultrasonic advertising platforms. Technical integration is expected to be completed in Q2 2025, with combined product offerings available for customer deployments in 2H 2025.\"Authenticated scalability and direct consumer engagement are no longer optional for brands seeking competitive differentiation,\" said Joseph Stonbely II, Founder & Executive Producer of Mission: IGNITION  \"We’ve long considered the NYIAX platform our most essential front-line resource for delivering meaningful, value-engineered brand","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datavault-ai-licenses-patented-adio-115700241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","ML","DVLT","PSQ","BK4141","MNQmain","TQQQ","USJW.SI","TSYW.SI","SQQQ","QID",".IXIC","NQmain","USAW.SI","QLD","NVIW.SI","IDE"],"gpt_icon":1},{"id":"2522608342","title":"Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US","url":"https://stock-news.laohu8.com/highlight/detail?id=2522608342","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522608342?lang=en_us&edition=fundamental","pubTime":"2025-03-25 01:20","pubTimestamp":1742836822,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (NYSE:ABT) has caught investor attention with the FDA’s approval of an Investigational Device Exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, a significant development within the realm of coronary artery disease treatment. This announcement comes in conjunction with the company's recent robust Q4 2024 earnings results, reporting net income and diluted EPS growth. Additionally, Abbott declared its 405th consecutive quarterly dividend and outlined...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-nyseabt-receives-fda-approval-for-corona","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1914381329.SGD","SG9999004303.SGD","LU2089984988.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","SG9999002232.USD","IE0009355771.USD","BK4082","LU1691799644.USD","IDE","LU1721429741.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","NYSE","LU2112291526.USD","LU2237957902.USD","BK4585","BK4588","LU0122379950.USD","LU0266013472.USD","LU0170899867.USD","BK4568","LU1989763690.USD","ABT","SGXZ23171101.USD","LU1989763427.SGD","BK4566","LU1057294990.SGD","LU1061106388.HKD","BK4504","LU2468319806.SGD","IE0002141913.USD","BK4533","LU2133065610.SGD","LU0234572021.USD","BK4581","LU1721429402.USD","LU0868494617.USD","SG9999002224.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU2237957811.SGD","BK4592"],"gpt_icon":0},{"id":"2521400898","title":"Anteris Reports One-Year Patient Outcomes for DurAVR® THV","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400898","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400898?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556600,"startTime":"0","endTime":"0","summary":"New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-yearMINNEAPOLIS and BRISBANE, Australia, March  21, 2025  (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/21/3047015/0/en/Anteris-Reports-One-Year-Patient-Outcomes-for-DurAVR-THV.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK4082","IDE"],"gpt_icon":0},{"id":"2520443767","title":"BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443767","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443767?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:50","pubTimestamp":1742467800,"startTime":"0","endTime":"0","summary":"FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ --BD  , a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption  clinical trial intended to advance BD's efforts to achieve Premarket Approval  from the U.S. Food and Drug Administration  for the use of GalaFLEX LITE Scaffold in decreasing capsular contracture  recurrence during breast revision surgery.\"This milestone marks a significant advancement in our efforts to achieve FDA Premarket Approval for our first breast indication for GalaFLEX LITE Scaffold and reinforces the company's commitment to improving patient outcomes through innovative technologies that reduce surgical complications,\" said Rian Seger,worldwide president of the BD Surgery business. \"Our team has worked closely with the FDA to help address a critical medical complication arising from implant-based breast surgery, and the first patient treated brings us closer to delivering a much-needed solution.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bd-announces-milestone-clinical-trial-105000559.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bd-announces-milestone-clinical-trial-105000559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985489474.SGD","LU1571399168.USD","LU0289739343.SGD","LU0385154629.USD","BK4504","LU1059921491.USD","LU0205194284.USD","BK4020","LU1150488135.SGD","LU0289961442.SGD","LU1894683348.USD","LU0240878834.USD","LU1854104046.USD","LU1150488218.USD","ADM","LU0471298777.SGD","LITE","LU0266013472.USD","LU0240877869.USD","LU0511384066.AUD","BK4098","LU0205193047.USD","LU0878866978.SGD","BDX","LU0068578508.USD","BK4189","LU0012050646.USD","CC","LU1894683264.USD","LU1854103824.USD","LU0985320562.USD","IDE","BK4588","BK4585","LU2211817866.USD","LU1489326972.SGD","IE00BFXG1179.USD","BK4082","LU0433182093.SGD","BK4597","LU0106261612.USD"],"gpt_icon":0},{"id":"2520802741","title":"Realtek to Showcase Datavault AI’s Acoustic Divisions WiSA E at Convergence India Expo, Featuring Solutions Supporting India’s AI and Blockchain Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2520802741","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520802741?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:15","pubTimestamp":1742390100,"startTime":"0","endTime":"0","summary":"Realtek and WiSA E to Demonstrate a SDK for the Set-Top Box Market Enabling Turnkey Multichannel Audio Powered by WiSA E and Realtek. This collaboration between Datavault AI and Realtek comes at a time in India’s digital transformation that aligns with the government’s initiatives in AI, blockchain, and secure data management. The addition of Data Vault and ADIO, patented AI and blockchain solutions, positions Datavault AI for enterprise contracting and seamless integration into India’s corporate, government, and transportation sectors. These advanced technologies offer innovative solutions in AI-driven data monetization, blockchain-based security, and intelligent engagement systems, making them ideal for large-scale infrastructure projects, telecom providers, smart cities, and financial institutions.Prime Minister Modi recently stated, \"Artificial intelligence, machine learning, Internet of Things, blockchain, and big data hold potential to take India to new heights of development and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/realtek-showcase-datavault-ai-acoustic-131500438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","CAGR","BK4141","ML","IDE","DVLT","BK4159"],"gpt_icon":0},{"id":"2520683236","title":"Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2520683236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520683236?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:30","pubTimestamp":1742243400,"startTime":"0","endTime":"0","summary":"VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION. Voya Global Advantage and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund   today announced important information concerning the Funds' distributions declared in February 2025. This press release is issued as required by the Funds' Managed Distribution Plan  and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the March distribution. It is not determinative of the tax character of the Funds' distributions for the 2025 calendar year. Shareholders should note that the Funds' total regular distribution amount","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FUND","LU0061475181.USD","NAV","IDE","IGA","BK4184","VOYA","LU1878469433.USD","LU0211331839.USD","ARKG"],"gpt_icon":0},{"id":"2520129688","title":"Press Release: Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2520129688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520129688?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:15","pubTimestamp":1742242500,"startTime":"0","endTime":"0","summary":"Voya Investment Management, the asset management business of Voya Financial, Inc. , announced today the distributions on the common shares of five of its closed-end funds: Voya Global Advantage and Premium Opportunity Fund , Voya Global Equity Dividend and Premium Opportunity Fund , Voya Infrastructure, Industrials and Materials Fund , Voya Asia Pacific High Dividend Equity Income Fund , and Voya Emerging Markets High Dividend Equity Fund .With respect to each Fund, the distribution will be paid on April 15, 2025, to shareholders of record on April 1, 2025. The ex-dividend date is April 1, 2025. The distribution per share for each Fund is as follows:. The following table sets forth an estimate of the sources of each Fund's February distribution and its cumulative distributions paid this fiscal year to date. Amounts are expressed on a per common share basis and as a percentage of the distribution amount.Estimated Sources                             Fiscal YTD                      Estima","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAV","IGA","IDE","BK4585","BK4232","IHD","BK4588","BK4022","BK4184","EQR","LU0211331839.USD","LU0061475181.USD","R","VOYA","BK4215","LU1878469433.USD","IGD","IAE"],"gpt_icon":0},{"id":"2520528488","title":"NYIAX Technology Platform Powered by Nasdaq Collaborates with Datavault AI’s Patented Information Data Exchange® through Co-Marketing and Technology Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2520528488","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520528488?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:07","pubTimestamp":1742213220,"startTime":"0","endTime":"0","summary":"Unlocking New Revenue Streams: Transforming Real-World Assets and Data into Financial Opportunities. BEAVERTON, Ore., March 17, 2025----Datavault AI Inc. , a leader in AI-driven data experience, valuation, and monetization, today announced a multi-year commercial and intellectual property  alliance with NYIAX, a pioneer in transparent trading technology built on the Nasdaq financial framework. This partnership will integrate Datavault AI’s patented Information Data Exchange  and award-winning Data Vault platform with NYIAX’s cutting-edge blockchain exchange technology. The collaboration leverages NYIAX's capabilities, enabling businesses to scale, list, price, and trade data and digital assets efficiently, creating new revenue opportunities. With the increasing recognition of data as a strategic financial asset, this partnership provides businesses with the infrastructure to monetize data in a secure and scalable environment, bridging the gap between data valuation and liquidity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nyiax-technology-platform-powered-nasdaq-120700432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","BK4136","NDAQ","MNQmain","PSQ","LU1481599808.USD","USJW.SI","TQQQ",".IXIC","IP","IE00B3QW5Z07.USD","III","USAW.SI","IE00BKPKM429.USD","BK4134","NQmain","SQQQ","DVLT","LU2095319765.USD","IDE","BK4112","BK4141","LU1487256676.USD","LU2210150020.SGD","QLD","BK4588","QID","NVIW.SI","TSYW.SI","BK4585","LU2210149790.SGD","LU1481600234.SGD","LU2463526074.USD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2518224585","title":"First Patient Enrolled in Merit Medical’s PREEMIE Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224585","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224585?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:25","pubTimestamp":1741613100,"startTime":"0","endTime":"0","summary":"Multicenter, prospective study designed to evaluate safety and efficacy of Bloom Micro Occluder System for treatment of patent ductus arteriosus in premature infantsSOUTH JORDAN, Utah, March  10, 2025","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039830/8028/en/First-Patient-Enrolled-in-Merit-Medical-s-PREEMIE-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","BK4198","MMSI","IDE"],"gpt_icon":0}],"pageSize":16,"totalPage":6,"pageCount":1,"totalSize":91}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDE\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"IDE","amount":0.1,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-15"},{"date":"2025-03-03","symbol":"IDE","amount":0.1,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-17","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-17"},{"date":"2025-02-03","symbol":"IDE","amount":0.1,"announcedDate":"2025-01-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-03","defaultRemindTime":1738593000000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-18","payableDate":"2025-02-03","currency":"USD","dateTimestamp":1738558800000,"payDate":"2025-02-18"},{"date":"2024-12-30","symbol":"IDE","amount":0.1,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-15","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2025-01-15"},{"date":"2024-12-02","symbol":"IDE","amount":0.1,"announcedDate":"2024-11-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-02","defaultRemindTime":1733149800000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-16","payableDate":"2024-12-02","currency":"USD","dateTimestamp":1733115600000,"payDate":"2024-12-16"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDE\",market:\"US\",,,undefined,":[{"executeDate":"2015-04-01","recordDate":"2015-04-06","paymentDate":"2015-04-15","value":0.405,"currency":"USD"},{"executeDate":"2015-07-01","recordDate":"2015-07-06","paymentDate":"2015-07-15","value":0.405,"currency":"USD"},{"executeDate":"2015-10-01","recordDate":"2015-10-05","paymentDate":"2015-10-15","value":0.365,"currency":"USD"},{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-15","value":0.365,"currency":"USD"},{"executeDate":"2016-04-01","recordDate":"2016-04-05","paymentDate":"2016-04-15","value":0.365,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDE\",market:\"US\",delay:false,,,undefined,":{}}}